«Expert RA» re-confirms Binnopharm Group’s credit rating of ruA
06.09.2024
Expert RA, the largest credit rating agency, confirmed Binnopharm Group’s creditworthiness of ruA with a stable outlook.
The rating was backed up by stable business growth rate, high margins, balanced financial policy, and comfortable level of debt burden. According to the agency assessment, the liquidity is high and the corporate risk indicator is low. There’s a high probability that the credit rating will not change within the coming year.
Khafiz Gafurov, Chief Financial Officer of Binnopharm Group: «Having the rating confirmed by an independent agency demonstrates the effectiveness of the Company’s business development strategy. Even with the current economic background and high key interest rate, Binnopharm Group continues on the path of active development. We have developed and are enforcing an action plan to diversify the loan portfolio and reduce the effective interest rate. The latest re-confirmation and future credit rating upgrade will empower the company to leverage bonds as one element the said plan».
Binnopharm Group is one of the leading pharmaceutical Russian companies that gathered manufacturing sites in different regions of the country. The AlphaRM analytical agency ranked the company 6th for pharmacy sales and second among domestic drug manufacturers among the leaders of the Russian market at the end of 2023. In the first half of 2024, Binnopharm Group demonstrated a one-and-a-half times market growth.
The rating was backed up by stable business growth rate, high margins, balanced financial policy, and comfortable level of debt burden. According to the agency assessment, the liquidity is high and the corporate risk indicator is low. There’s a high probability that the credit rating will not change within the coming year.
Khafiz Gafurov, Chief Financial Officer of Binnopharm Group: «Having the rating confirmed by an independent agency demonstrates the effectiveness of the Company’s business development strategy. Even with the current economic background and high key interest rate, Binnopharm Group continues on the path of active development. We have developed and are enforcing an action plan to diversify the loan portfolio and reduce the effective interest rate. The latest re-confirmation and future credit rating upgrade will empower the company to leverage bonds as one element the said plan».
Binnopharm Group is one of the leading pharmaceutical Russian companies that gathered manufacturing sites in different regions of the country. The AlphaRM analytical agency ranked the company 6th for pharmacy sales and second among domestic drug manufacturers among the leaders of the Russian market at the end of 2023. In the first half of 2024, Binnopharm Group demonstrated a one-and-a-half times market growth.
